Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnosis and treatment of ANCA-associated vasculitis : S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for ENT Medicine and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025
Same author

[Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025
Same author

[Corona vaccination under immunosuppression].

Zeitschrift fur Rheumatologie·2024
Same author

[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].

Zeitschrift fur Rheumatologie·2023
Same author

Point-of-care COVID-19 antigen testing in German emergency rooms - a cost-benefit analysis.

Pulmonology·2021
Same author

Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals.

Pneumologie (Stuttgart, Germany)·2021
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

[Tuberculosis : diagnostics and prophylaxis].

N Görl1, R Diel, C Kneitz

  • 1Klinik für Innere Medizin II, Rheumatologie/Immunologie, Klinikum Südstadt Rostock, Deutschland. norman.goerl@kliniksued-rostock.de

Zeitschrift Fur Rheumatologie
|December 6, 2011
PubMed
Summary
This summary is machine-generated.

Latent tuberculosis infection, a dormant state of Mycobacterium tuberculosis, can reactivate due to immune suppression. Interferon-gamma release assays (IGRAs) now aid in differentiating infection from BCG vaccination, guiding treatment with isoniazid.

Related Experiment Videos

Last Updated: May 27, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pulmonology

Context:

  • Mycobacterium tuberculosis infection leads to lung granulomas.
  • Latent tuberculosis infection (LTBI) poses a risk for reactivation, particularly with compromised immunity.
  • Traditional diagnostic methods include anamnesis, radiography, and bacteriology (microscopy, culture, PCR).

Purpose:

  • To discuss the diagnosis and management of latent tuberculosis infection.
  • To highlight the advent and utility of interferon-gamma release assays (IGRAs).
  • To emphasize the role of IGRAs in differentiating M. tuberculosis infection from BCG vaccination and in screening for immunosuppressive therapy.

Summary:

  • Latent tuberculosis infection (LTBI) is a significant clinical concern due to potential reactivation.
  • Interferon-gamma release assays (IGRAs) offer improved diagnostic accuracy over the tuberculin skin test, distinguishing M. tuberculosis infection from Bacillus Calmette-Guérin (BCG) vaccination.
  • IGRAs are crucial for pre-treatment screening before initiating tumor necrosis factor-alpha (TNF-α) inhibitor therapy.
  • Recommended treatment for LTBI involves a 9-month course of isoniazid.

Impact:

  • IGRAs enhance the precision of tuberculosis screening, especially in vaccinated populations.
  • Improved diagnostics facilitate timely intervention, preventing LTBI reactivation.
  • This approach is vital for patient safety prior to immunosuppressive therapies like TNF-α inhibitors.
  • Effective management of LTBI reduces disease progression and transmission.